TMEM16A-also called ANO1, TAOS2, or DOG1-is the prototype of a family of Ca 21 -activated Cl 2 channels, with eight conserved transmembrane domains (Caputo, et al. 2008; Schroeder, et al. 2008; Yang, et al. 2008) . TMEM16 family members are widely expressed and contribute to fluid secretion in epithelia, contraction in smooth muscle, and excitability in neurons (Gomez-Pinilla, et al. 2009; Huang, et al. 2009; Hwang, et al. 2009; . Early evidence identified amplification of chromosomal region 11q13 containing the TMEM16A gene in HNSCC (Akervall, et al. 1995) , gastrointestinal stromal tumors (GIST) (Berglund, et al. 2014; Liu, et al. 2015) , breast cancer (Wu, et al. 2015) , and esophageal cancer (Huang, et al. 2006; Huang, et al. 2002) but its significance in growth pathways was not realized until recently (Duvvuri, et al. 2012; Katoh and Katoh 2003) .
A handful of studies have attempted to address clinical and biochemical significance of TMEM16A in solid tumor growth. The amplification and the overexpression in HNSCC and breast cancer were shown to correlate with poor patient survival (Akervall, et al. 1995; Britschgi, et al. 2013; Duvvuri, et al. 2012; Ruiz, et al. 2012 ).
TMEM16A was shown to activate effectors of tumor growth including, ERK1/2 and AKT1 in vitro and in vivo (Britschgi, et al. 2013; Duvvuri, et al. 2012 ). Subsequently, TMEM16A interaction with the ERM (ezrin/ radixin/moesin) proteins (Shiwarski, et al. 2014) or EGFR (Bill, et al. 2015a; Britschgi, et al. 2013 ) was proposed to regulate pathways of motility or growth. TMEM16A-induced mechanisms that promote tumor growth and survival are far from being clear, but evidence points to its ability to recruit EGFR, an oncogenic receptor of the HER family.
Earlier studies suggested that the putative "pore-forming" region of TMEM16A allowing for transmembrane flux of Cl 2 ions was located within transmembrane domains 5-6 (amino acids 642-672), and activation of conductance function occurred by Ca 21 binding in the Nterminus and the short loops between transmembrane domains or by TMEM16A dimerization (Terashima, et al. 2013; Tien, et al. 2014 ).
More recent findings obtained using TMEM16A mutants have suggested another view; it was proposed that amino acid sequence 728-752 following domains 5-6, forms a partial re-entrant finger within the membranous space, allowing Ca 21 -sensing and Cl 2 flux (Bill, et al. 2015b; Tien, et al. 2014) . Regardless of the reported differences in the proposed mechanism of action, the Cl 2 conductance function of TMEM16A appears to recruit a growth pathway. Consistently, small molecule inhibitors of Cl 2 channel activity are capable of suppressing growth of HNSCC and breast cancer cells with 11q13 amplification (Britschgi, et al. 2013; Duvvuri, et al. 2012) . Moreover, TMEM16A mutants (K668E, K610A, and R621E) that affect Cl 2 conductance also affect cell viability (Britschgi, et al. 2013; Duvvuri, et al. 2012; Yang, et al. 2008) . Therefore, as we begin to understand ways in which TMEM16A is regulated, biochemical evidence opens up a distinct possibility, that TMEM16A Cl 2 conductance function is connected to a tumor growth pathway. Moreover, with the ability to interact with EGFR, TMEM16A is a molecule of potential translational significance in solid tumor biology (Bill, et al. 2015a) .
In this study, we have explored a potential link between TMEM16A-induced Cl 2 conductance and pathway(s) of cell growth and survival in HER2-amplified breast cancer and HNSCC. Furthermore, we have explored the involvement of this link in the regulation of responses to EGFR/HER-family-based biologically targeted therapies, namely, the anti-HER2 therapy, trastuzumab, and the anti-EGFR therapy, cetuximab.
| MATERIALS A ND METHODS

| Materials
The anti-TMEM16A antibody was from Thermo Scientific (Waltham, MA), anti-b-tubulin antibody was from Abcam (Cambridge, UK), and anti-EGFR antibody was from Santa Cruz Biotechnology (Dallas, TX).
Antibodies to phosphotyrosine Y1068 EGFR, HER2, phosphotyrosine Y1248 HER2, plexin B1, STAT3, and phosphotyrosine Y705 STAT3
were from Cell Signaling (Danvers, MA 
| Cell lines and media
SKBR3 breast cancer cells were chosen for study due to HER2-positivity and because of a previously described model of trastuzumab resistance (Kulkarni, et al. 2010 ) and were obtained from previous work conducted by Kulkarni overerexpressing cells were generated by transduction of viruses as described previously (Duvvuri, et al. 2012 a doxycycline-inducible manner as described previously (Britschgi, et al. 2013 ) and were from the authors Bill and Gaither at Novartis. Induction of shRNA was performed by adding 10ng/mL doxycycline to the growth medium. These cells were cultured in DMEM containing 10% 
| Plasmids and transfection
Plasmid DNAs encoding TMEM16A mutants (E727K and L759Q) were described previously (Bill, et al. 2015b) . DNA was mixed with Lipofectamine 2000 in OPTI-MEM and complexes were layered over OSC-19 cells. Cells were allowed to recover for 48 h followed by solubilization and analysis in western blots.
| Western blot assay
Cells were cultured and treated as indicated followed by solubilization in cold RIPA buffer containing protease and phosphatase inhibitors.
Insoluble material was removed by centrifugation at 13,000 rpm for 10 min at 48C and solubilized protein was estimated by Bradford's method. For analysis in western blots, equal amounts of protein were denatured, separated in 8% acrylamide gels, and transferred to nitrocellulose membrane. Membranes were incubated with the indicated primary antibodies followed by detection with HRP-coupled secondary antibody.
The blots in Figure 3 were developed using the LiCor imaging system. Briefly, equal amounts of protein from cells cultured in the indicated conditions were loaded into 8% SDS-PAGE gels and subsequently transferred to nitrocellulose membrane. These membranes were then exposed to the indicated primary antibody and then exposed to a secondary antibody for use with the LiCor system. Densitometry values were obtained using the LiCor imaging software.
Any imaging changes (brightness, contrast) performed on blots were applied uniformly to maintain image integrity. Blots are cropped for conciseness; all full-length, uncropped blots are available in Supporting Information.
| Tumor xenograft analysis
Equal numbers (1.5 3 10 6 ) of OSC-19 control or TMEM16A-overexpressing cells were implanted in 100 mL of matrigel subcutaneously in nude mice. All mice were euthanized, tumors were removed, and weights were recorded at an arbitrary time point in accordance with IACUC University of Pittsburgh protocols. Lysates of tumors were prepared and protein was estimated. Equal amounts of protein were separated in 8% gels and detected in western blot analyses with the indicated antibodies using the LiCor imaging system (LiCor Odyssey Classic). All experimental protocols were approved by the IACUC at the University of Pittsburgh. All animal handling was performed in accordance with guidelines approved by the IACUC at the University of Pittsburgh.
| Fluorescence microscopy
Fluorescence microscopy was used to measure changes in intracellular 50 ng/mL EGF for 5 min followed by a return to normal Ringers. Cl 2 flux was calculated as the rate of change in fluorescence during the transition to low (and normal) chloride, using a linear fit of the slope.
| Whole cell patch clamp
Whole-cell patch clamp was conducted as described (Zhou, et al. 2015) .
Briefly, NMDG-Cl solutions were used to isolate Cl 2 currents from UM-SCC-1 cells overexpressing TMEM16A (bath solution was 140 mM NMDG-Cl, 10 mM HEPES, 1 mM MgCl 2 , 1.5 mM CaCl 2 , 5 mM glucose;
pipette solution was 140 mM NMDG-Cl, 10 mM HEPES, 1 mM MgCl 2 , 5 mM glucose, 1 mM EGTA, 1 mM Mg-ATP, and 0.1 mM Na-GTP). Membrane current (I m ) was measured using a periodic current-voltage (I/V) protocol, which stepped the holding potential from 100 to 1100 mV in 20 mV steps. Bath solution 6 agonists heated to 378C was perfused over the cell at 2 mL/min. The percent change in I m was calculated at the 60 mV holding potential. All cells tested exhibited outward rectified I/V curves with a reversal potential equal to the Cl 2 equilibrium potential, consistent with TMEM 16 A activity.
| Statistical analysis
All data are expressed as mean 6 SEM. Statistical analyses were performed with GraphPad Prism software using the Student's t-test or ANOVA, as appropriate (*P < .05; **P < .01; ***P < .001; ns, not significant).
induces a loss of expression and activity of EGFR and HER2 and decreases survival of HER2-amplified breast cancer cells
Previously, TMEM16A knockdown in breast cancer cells with 11q13 amplification was shown to suppress EGFR activity and colony formation (Britschgi, et al. 2013) . A distinct aggressive subtype of breast cancer that affects 25% patients harbors HER2 amplification. HER2's ability to connect to pathways of tumor growth depends on a close partnership with EGFR. The EGFR-HER2 partnership stimulates activity of the transcription factor, STAT3, an effector of cell survival and growth. To understand the significance of TMEM16A in the regulation of EGFR and HER2, HER2-amplified SKBR3 cells were treated with T16A-inhAO1, a small molecule inhibitor of TMEM16A Cl 2 channel activity or untreated as controls. EGFR phosphorylation and expression was found to decrease in T16A-inhAO1-treated cells compared to controls ( Figure 1A ). As TMEM16A inhibition suppressed EGFR, the effect on HER2 was also assessed-both HER2 expression and activity were reduced.
To investigate the effect of TMEM16A inhibition downstream from EGFR-HER2, activity of pY705 STAT3 was assessed. Activity was found to decrease without affecting STAT3 levels. Recently inhibitors of TMEM16A Cl 2 channel activity were proposed to function by influencing protein stability and/or internalization ).
Consistently, some loss of TMEM16A too was detectable in SKBR3 cells exposed to T16A-inh without causing significant changes in Plexin B1, another membrane-bound protein.
As a negative control, Cal-33 HNSCC cells, which are endogenously devoid of TMEM16A, were treated with T16A-inhAO1 (Supporting Information, Figure 1 ). While T16A-inhAO1 did affect the phosphorylation of EGFR, it did not alter the total EGFR expression, as demonstrated in the SKBR3 cells. Furthermore, phosphorylation of STAT3 was unaffected by T16A-inhAO1 suggesting that minor changes in phosphorylation of membrane receptors did not affect intracellular signaling.
Taken together these data suggest that TMEM16A Cl 2 channel activity is linked to the regulation of expression and activity of EGFR/ HER family members and STAT3, and therefore, any alterations of its function are likely to influence not only tumor growth but also responses to EGFR/HER family based therapy.
Whether HER2 and TMEM16A could be co-targeted was evaluated by measuring survival of SKBR3 cells treated with trastuzumab and T16A-inhAO1, individually or in combination ( Figure 1B ). Individual treatments with trastuzumab or T16A-inhAO1 reduced cell survival, whereas IgG, used as a control, had no effect. Combining trastuzumab and T16A-inhAO1 further inhibited cell survival in a cooperative Figure 1C ).
Previous studies have demonstrated that RNAi inhibition of TMEM16A (Britschgi, et al. 2013) leads to apoptotic activation and cell death as evidenced by increased PARP and caspase cleavage. To extend these studies, we engineered FaDu cells, with high endogenous TMEM16A expression, to contain doxycycline inducible control, nontargeting (NT) shRNA or shRNA against TMEM16A (Britschgi, et al. 2013 ) and assessed for viability following TMEM16A knockdown (Supporting Information, Figure 2 ). (Kulkarni, et al. 2010 ) of acquiredresistance to the anti-HER2 antibody trastuzumab was utilized in the study.
To confirm resistance, viability of parent and resistant SKBR3 cells was assessed after treatment with trastuzumab (Supporting Information, Figure 3A) . A growth-inhibitory response to trastuzumab was Figure 3C ). The upregulation in the resistant SKBR3 cells was specific to TMEM16A, as no increase in EGFR or HER2 ) was detectable by western blot (Supporting Information, Figure 3D ).
To investigate whether the change in TMEM16A expression influences sensitivity to TMEM16A inhibition, viability was assessed in parent and trastuzumab-resistant cells treated with T16A-inhAO1.
TMEM16A inhibition led to a loss of viability in both cell types; however, the resistant cells showed a twofold greater inhibition compared to parent cells (Figure 2A) . Furthermore, combined treatment with trastuzumab and T16A-inhAO1 suppressed colony formation in both cell types, whereas treatment with trastuzumab alone had a little or no effect ( Figure 2B,C) .
Together, these data support the conclusion that HER2-resistant cells increasingly rely on TMEM16A-induced survival mechanisms and therefore, are more sensitive to its inhibition. These data also raise the possibilities that in certain tumor cells, TMEM16A cooperates with members of the EGFR/HER family, imparting sensitivity to EGFR/HER family-based therapy. Furthermore, combined suppression of TMEM16A and EGFR/HER receptors may inhibit growth and reverse/ delay resistance more effectively, thus, providing a clinical advantage.
FIG URE 1 TMEM16A influences expression and activation of EGFR/HER family members and a pathway of survival in ErbB2/ HER2 amplified breast cancer cells. A, SKBR3 cells were plated on 60 mm plates and allowed to attach for 2 h. Cells were left untreated as a control or treated with T16A-inh (40 mM) for 1.5 h at 378C. Cells were lysed to obtain solubilized protein and equal amounts of protein were analyzed for pY1068 EGFR, EGFR, b-tubulin, pY1248 HER2, HER2, pY705 STAT3, STAT3, TMEM16A, and Plexin B1 in western blots. B, SKBR3 cells (3 3 10 3 /well) were plated in 96-well plates in quadruplicate and left untreated as controls or treated with human IgG or trastuzumab (20 mg/mL each) or T16A-inh (5 mM). All treatments were carried out for 3 days at 378C followed by measurements of viability with the CellTiter-Glo reagent. Readings from the treated group were normalized to the readings from control. Representative data from triplicate results (N 5 3) are presented as mean 6 SEM. The significance (***P < .001) was determined from one-way ANOVA analysis. C, SKBR3 cells (3 3 10 3 /well) were plated in 96-well plates in quadruplicate and left untreated as controls or treated with trastuzumab (20 mg/mL) or trastuzumab plus varying concentrations of Cacc-inh (0.5-30 mM). All treatments were carried out for 3 days at 378C followed by measurements of viability with the CellTiter-Glo reagent. Readings from the treated group were normalized to the readings from controls. Representative data from triplicate results (N 5 3) are presented as mean 6 SEM. The significance (***P < .001) was determined from one-way ANOVA analysis 3.3 | TMEM16A interacts with and activates EGFR in non-11q13 amplified HNSCC cells
Interactions between TMEM16A and EGFR play a critical role in tumor growth in 11q13 amplified HNSCC (Britschgi, et al. 2013) . Figure 3C ). Furthermore, following TMEM16A knockdown, EGF stimulation did not significantly increase the phosphorylated fraction of EGFR ( Figure 3C ), suggesting that TMEM16A may play a role in sensitizing EGFR to EGF stimulation.
Taken together, TMEM16A appears to interact with and promote EGFR-induced early signaling events in HNSCC growth pathways. Representative data from triplicate results (N 5 3) are presented as mean 6 SEM. The significance (***P < .001) was determined from one-way ANOVA analysis. B, SKBR3 cells, parent or trastuzumabresistant, (1 3 10 3 /well) were plated in 6-well plates. Cells were allowed to attach overnight after which cells were left untreated as controls or treated with trastuzumab alone (10 mg/mL) or trastuzumab (10 mg/mL) combined with T16A-inh (1 or 5 mM). Treatments were repeated every 2-3 days for a period of 2-3 weeks. Plates were fixed and stained with crystal violet. A representative plate from triplicate results (n 5 3) is shown. C, The number of colonies for each condition from independent experiments (N 5 3) was counted. The numbers obtained for the treated groups were normalized to the control group. Data are presented as mean 6 SEM of triplicate results (N 5 3) 
| EGF does not have a direct influence on TMEM16A activity or function in HNSCC
| Inhibition of TMEM16A improves response to EGFR targeting antibody in HNSCC
EGFR is highly expressed and involved in promotion of oncogenic growth in 80-90% HNSCC, but cetuximab is the only FDA-approved biologic therapy targeting EGFR (Vermorken, et al. 2007) . It is now known that 10-13% HNSCC patients benefit from cetuximab therapy and the remaining are nonresponsive (Vermorken, et al. 2007 ). As our data support involvement of TMEM16A in the regulation of EGFR activation and expression in HNSCC, we sought to investigate whether simultaneous inhibition of TMEM16A and EGFR can improve response to cetuximab. Therefore, OSC-19 cells were treated with cetuximab, T16A-inhAO1 or a combination of both inhibitors and cell viability was analyzed ( Figure 4A,B) ; the combination decreased cell viability more effectively. Another TMEM16A inhibitor, Cacc-inhAO1 also decreased viability in cells treated with cetuximab as compared to cetuximab alone ( Figure 4C ). Together these data suggest that the co-inhibition of . Cells were treated also with cetuximab (20 mg/ mL) and T16A-inh (20 mM) together. All treatments were carried out for 4 days at 378C. Viability was measured with the CellTiterGlo reagent. Readings from the treated groups were normalized to the readings from the control. Representative data from triplicate results (N 5 3) are presented as mean 6 SEM. The significance (***P < .001) was determined from one-way ANOVA analysis. B, OSC-19 cells (3 3 10 3 /well) were plated in 96-well plates in quadruplicate and left untreated as controls or treated with cetuximab (20 mg/mL) or cetuximab along with varying concentrations of T16A-inh (1-20 mM). All treatments were carried out for 3 days at 378C followed by measurements of viability with the CellTiter-Glo reagent. Readings from the treated groups were normalized to the readings from the controls. Representative data from triplicate results (N 5 3) are presented as mean 6 SEM. The significance (***P < .001) was determined from one-way ANOVA analysis. C, OSC-19 cells (3 3 10 3 /well) were plated in 96-well plate in quadruplicate and left untreated as controls or treated with cetuximab (20 mg/mL) or cetuximab along with varying concentrations of Cacc-inh (0.5-30 mM). All treatments were carried out for 3 days at 378C followed by measurements of viability with the CellTiterGlo reagent. Readings from the treated group were normalized to readings from the controls. Representative data from triplicate results (N 5 3) are presented as mean 6 SEM. The significance (***P < .001) was determined from one-way ANOVA analysis support the possibility that TMEM16A interacts with and plays a role in regulating EGFR and HER2.
To Although the physical location of or exact primary sequence that conforms to the TMEM16A Cl 2 "pore forming region" is not known (Bill, et al. 2015b; Britschgi, et al. 2013; Terashima, et al. 2013; Tien, et al. 2014; Yang, et al. 2008 
FIG URE 5
Cl 2 channel function of TMEM16A regulates activity of EGFR pathway. A, SKBR3 cells were plated in 60 mm plates and allowed to attach for 2 h. Cells were subjected to medium containing a physiologically normal level of Cl 2 as a control (N) or medium in which Cl 2 was depleted (low) for 3 h at 378C. Cells were lysed to obtain solubilized protein and equal amounts of protein were analyzed for pY1068 EGFR, EGFR, pY705 STAT3, and b-tubulin in western blots. B, OSC-19 cells were plated in 60 mm plates and allowed to attach for 2 h. Cells were subjected to medium containing physiologically normal level of Cl 2 as a control (N) or T16A-inh (40 mM) and also to medium in which Cl 2 was depleted (Low). All treatments were carried out for 2.5 h at 378C at which time cells were lysed to obtain solubilized protein. Equal amounts of protein were analyzed for pY1068 EGFR, EGFR, pY705 STAT3, and b-tubulin in western blots. C, OSC-19 cells were plated in 100 mm plates in triplicate. One plate was mock-transfected as a control and the other two were transfected with plasmids encoding TMEM16A mutants (E727K or L759Q) known to be deficient in Cl 2 channel activity. Cells were lysed to obtain solubilized protein that was analyzed for TMEM16A, EGFR, pY705 STAT3, and b-tubulin in western blots 3.7 | Voltage-gated chloride (CLC) and potassiumchloride co-transporter (KCC) have no effect on EGFR protein
Although TMEM16A interacts with EGFR and aids EGFR-signaling in cancer cells (Bill et al., 2015a) , it remains unclear if other chloride channels can impact EGFR signaling in cancer cell lines. Therefore, it was of interest to study the effect of voltage-gated (CLC) and potassium-(KCC) chloride cotransporter on EGFR signaling. Recent studies have
shown that voltage-gated ion channels, specifically the chloride channels (CLC) have crucial roles in regulating cell proliferation, thereby influencing the development and progression of cancer (Rao et al., 2015) . Analysis of TCGA data via cBioPortal revealed that CLC-2, -4, and -7 were most frequently altered in HNSCC and invasive breast carcinoma (Supporting Information, Figure 7 ). RT-PCR profiling of cancer cell lines for CLC-2, -4, and -7 showed that these genes were expressed, and that CLC-2 and -4 were most abundantly expressed (Supporting Information, Figure 8A ). We did not detect expression of K-Cl cotransporter (KCC) overexpression has been associated with enhanced tumor cell malignancy and invasiveness in a variety of cancers (Kitagawa, et al. 2013) . To evaluate whether KCC affects EGFR expression, we used DIOA, a known KCC pharmacological inhibitor in two HNSCC cell lines. However, in our results, the KCC inhibitor DIOA did not alter phosphorylated or total EGFR levels (Supporting Information, Figure 9 ).
| DISCUSSION
Chromosomal band 11q13 is frequently amplified in subtypes of GIST, breast cancer, HNSCC, and esophageal cancer (Berglund, et al. 2014; Britschgi, et al. 2013; Duvvuri, et al. 2012; Liu, et al. 2015; Ruiz, et al. 2012 shown to contribute to pathways involved in solid tumor growth and progression (Ayoub, et al. 2010; Britschgi, et al. 2013; Duvvuri, et al. 2012 ). The molecular mechanisms that connect TMEM16A to tumor growth are not well understood, but in breast cancer and HNSCC patients, 11q13 amplification correlates with TMEM16A protein overexpression and poor clinical outcome (Britschgi, et al. 2013; Duvvuri, et al. 2012) . Moreover, TMEM16A contributes to tumor growth and viability even in the absence of 11q13 amplification (Duvvuri, et al. 2012 ). Wu et al. (2015) have previously shown that TMEM16A expression correlates with clinical outcome in breast cancer independently of HER2 expression (Wu, et al. 2015) . However, the effect of HER2 blockade on TMEM16A expression was not investigated in these studies and, hence, the present experiment was designed to explore the significance of interaction between TMEM16A and HER-family proteins. Based on our data, we suggest that TMEM16A may regulate HER-family signaling and may be altered in the context of trastuzumab treatment. Further work is needed to ascertain if this idea can be confirmed in a clinical setting.
In this study, we have explored the possibility that the inhibition of expression and an increased sensitivity to its inhibition, suggesting increased molecular dependence on TMEM16A-dependent growth pathways. Moreover, considering that cross-activation among EGFR and other members of HER family are known causes of trastuzumab resistance (Yarden 2001) , and that TMEM16A is a regulator of the EGFR pathway (Britschgi, et al. 2013 ), TMEM16A dysregulation may very well result in resistance to other EGFR/HER targeted therapies.
Our data implicate TMEM16A as a therapeutic target in solid tumors demonstrating resistance to EGFR/HER-targeted therapies.
How TMEM16A induces resistance to EGFR/HER family-based therapies, including trastuzumab and cetuximab, is not clear, but considering that TMEM16A interacts with EGFR (Britschgi, et al. 2013 Moreover, changes in the Cl 2 flux across the membrane may affect cellular site-specific signaling by influencing internalization of total and/or phosphorylated receptor or ligand secretion . However, these data should be interpreted with caution, as manipulation of ionic content can have nonspecific effects on plasma membrane integrity and potential (Zhou, et al. 2015) . The observed changes in the expression of total and phosphorylated forms of EGFR and HER2 in cells treated with TMEM16A inhibitors support the involvement of receptor internalization or trafficking processes (Bill, et al. 2015a; ). Knockdown of TMEM16A in breast cancer cells not only reduces EGFR phosphorylation but also influences the autocrine pathway of ligand secretion (Britschgi, et al. 2013) . The levels of secreted cytokines, EGF and TGF, were decreased in cells in which TMEM16A expression was knocked down, whereas overexpression of TMEM16A was sufficient to promote secretion. Although a similar effect on ligand secretion was not measurable in HNSCC cell lines, its existence or activation under certain condition was not ruled out (Britschgi, et al. 2013) .
Notably, stimulation of EGFR with EGF did not alter the activity of TMEM16A in UM-SCC-1 cells, indicating that the TMEM16A activity may not be regulated by EGFR as shown in other cells lines (Jeulin, et al. 2008; Mroz and Keely 2012) . Taken together, the activation of TMEM16A Cl 2 channel function influences early signaling events, including the regulation of EGFR/HER2 expression and phosphorylation and, thus, impacts the response or resistance to biologic therapy of EGFR/HER family members. Our data do not exclude the possibility that TMEM16A has functions that are independent of its channel function. It remains plausible that TMEM16A can interact with members of the EGFR family independently of its channel function, and that channeldeficient TMEM16A mutants of may have altered membrane stability.
A majority of HNSCC patients, despite the expression of wild-type EGFR, are found nonresponsive to biologic inhibition of EGFR mediated by cetuximab (Pai and Westra 2009; Vermorken, et al. 2007 ).
HNSCC are thus thought to harbor other unknown but essential regulators of EGFR and its downstream targets that are capable of influencing therapeutic outcome (Leemans, et al. 2011; Tian, et al. 2011 ).
Recently, involvement of TMEM16A in the activation of RAS-RAF-ERK1/2 signal transduction pathway of tumor growth was described in HNSCC (Duvvuri, et al. 2012) . Furthermore, TMEM16A function as a signal transducer was proposed to associate with its function to regulate Cl 2 flux (Duvvuri, et al. 2012) . Our data suggest that the manipula- (Bill, et al. 2015a) . Whether TMEM16A overexpression predicts sensitivity to cetuximab therapy remains to be explored in a clinical setting, but as presented here, the 11q13-amplified FaDu cells expressing TMEM16A shRNA show an increase in cetuximab-response, suggesting that combined targeting of TMEM16A and EGFR maybe efficacious in selected patients.
In summary, we have described a molecular connection between TMEM16A, a Ca 21 activated Cl 2 channel, and members of the EGFR/
HER family that appears to be, in part, mediated by Cl 2 flux through the channel. By regulating the expression and the activity of EGFR/ HER family members, TMEM16A impacts tumor cell growth and viability signaling and, therefore, the response to antibody-mediated EGFR/ HER family-targeted biologic therapies in breast cancer and HNSCC.
Our data support the combination of TMEM16A along with members of the EGFR/HER family as a strategy to increase response to EGFR/ HER-targeted therapy and to delay or prevent emergence of resistance.
